id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-E-0250-0007,FDA,FDA-2005-E-0250,Certificate Extending Patent Term from U.S. Patent and Trademark Office to Novartis,Rule,Certificate Extending Patent Term,2007-03-15T04:00:00Z,2007,3,,,2025-12-02T20:44:38Z,,0,0,0900006480444239
FDA-2005-E-0250-0006,FDA,FDA-2005-E-0250,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-09-08T04:00:00Z,2006,9,,,2025-12-02T20:43:15Z,,0,0,0900006480444238
FDA-2005-E-0250-0005,FDA,FDA-2005-E-0250,Determination of Regulatory Review Period for Purposes of Patent Extension; ENABLEX,Notice,General Notice,2006-01-30T05:00:00Z,2006,1,2006-01-30T05:00:00Z,,2025-12-02T20:41:06Z,E6-1072,0,0,0900006480444237
FDA-2005-E-0250-0004,FDA,FDA-2005-E-0250,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-01-11T05:00:00Z,2006,1,,,2025-12-02T20:37:35Z,,0,0,0900006480444236
FDA-2005-E-0250-0003,FDA,FDA-2005-E-0250,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2005-07-18T04:00:00Z,2005,7,,,2025-12-02T20:35:50Z,,0,0,0900006480444235
FDA-2005-E-0250-0002,FDA,FDA-2005-E-0250,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2005-07-15T04:00:00Z,2005,7,,,2025-12-02T20:34:10Z,,0,0,0900006480444234
FDA-2005-E-0250-0001,FDA,FDA-2005-E-0250,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2005-06-22T04:00:00Z,2005,6,,,2025-12-02T20:30:31Z,,0,0,0900006480444216